Neupogen (filgrastim) Market Growth Outlook: Trends, Market Size, and Opportunities Over the Next Decade
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Drivers Are Shaping the Growth and Development of theNeupogen (filgrastim) Market?
The neupogen (filgrastim) market is anticipated to thrive due to the increasing prevalence of various illnesses. Diseases are body abnormalities causing specific symptoms or affecting certain areas, often the result of infections, genetics, environmental factors, or lifestyle choices. The rising occurrence of different diseases is powered by factors such as ageing populace, sedentary lifestyles, escalating pollution, poor diet, and the worldwide dispersal of contagious pathogens. Neupogen (filgrastim) addresses chemotherapy-induced neutropenia complexities by instigating the formation of neutrophils, hence boosting the capacity of the immune system to battle infections in patients with compromised immunity. It plays a vital role in reducing hospitalization rates, managing infection risks, and facilitating continuous cancer treatment plans for patients undergoing strenuous therapies. In 2024, according to Allergy UK, over 21 million individuals in the UK suffered from allergies, which in 2022 became the most reported chronic health issue. Predictions suggest that by 2026, at least one allergy will affect half of Europe’s population. Moreover, in 2022, data from Macmillan Cancer Support showed that cancer touched 3 million people in 2022, and it is forecasted to rise to almost 3.5 million by 2025 and 4 million by 2030 within the UK. Hence, the escalating prevalence of various diseases is fuelling the growth of the neupogen (filgrastim) market. Government-backed healthcare research and development initiatives are set to boost Neupogen (filgrastim). Government initiatives can be actions, programs, policies, or projects carried out by government bodies at different levels to address specific problems, fulfill certain objectives, or effect positive societal changes. Several authorities are supporting aspects like the neupogen (filgrastim) through various healthcare initiatives. For example, in 2022, the Department of Health and Social Care in the UK announced a £260 million (US $270.65 million) funding to stimulate healthcare research and manufacturing. It was committed by BEIS and DHSC to back NHS-led health research into diagnostics and treatment through new privacy-preserving platforms and clinical research services. An additional £60 million (US $63.60 million) was aimed at expanding UK’s life sciences manufacturing. Therefore, such government-led research and development drive the neupogen (filgrastim) market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19910&type=smp
#What is the Projected CAGR for the Neupogen (filgrastim) Market Size from 2025 to 2034?
The neupogen (filgrastim) market has shown steady growth. It will grow from $1,330.69 million in 2024 to $1,404.70 billion in 2025 at a CAGR of 5.6%. Growth factors include increased cancer cases, more awareness of chemotherapy-related neutropenia, better medical infrastructure, early biosimilar access, and healthcare spending increases.
The Neupogen (filgrastim) market is anticipated to grow, reaching $1,727.05 million by 2029 at a CAGR of 5.3%. Growth will be supported by heightened demand for affordable neutropenia treatments, broader healthcare access in developing nations, governmental backing for biosimilar adoption, a stronger focus on customized treatment approaches, and a growing elderly population. Notable trends include investment surges in biosimilar R&D, innovation in neutropenia drug delivery, expanded commercial collaborations in oncology, affordability initiatives, and development of new-generation G-CSF drugs.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19910
Which Cutting-Edge Market Trends Are Expected to Drive theNeupogen (filgrastim) Market’s Growth?
The main trend in the Neupogen (filgrastim) market is the focus on the development of breakthrough products in the form of cost-effective filgrastim biosimilar solutions, which will serve as accessible alternatives for managing chemotherapy-induced neutropenia. Filgrastim biosimilars are biological drugs that closely replicate the original Neupogen in terms of safety, efficacy, and structure. Their primary function is to boost the production of neutrophils in patients receiving chemotherapy to prevent neutropenia. For example, in November 2022, two US-based companies, Amneal Pharmaceuticals and Kashiv Biosciences, introduced Releuko (filgrastim-ayow), a biosimilar referencing Neupogen (filgrastim), to the US market. Releuko is available in intravenous and subcutaneous versions, offering healthcare providers dosing flexibility in single-use vials and prefilled syringes. Crucially, it offers a cost-effective therapeutic solution for chemotherapy-induced neutropenia, improving accessibility to vital oncology care and responding to the growing market demand for biosimilars.
What Are the Leading Market Players Impacting theNeupogen (filgrastim) Market’s Growth Trend?
Major companies operating in the neupogen (filgrastim) market include Amgen Inc.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/neupogen-filgrastim-global-market-report-
How Are the Key Segments of the Neupogen (filgrastim) Market Driving Opportunities and Innovations?
The neupogen (filgrastim)market covered in this report is segmented –
1) By Drug Type: Biologic; Biosimilar
2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=19910&type=smp
What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theNeupogen (filgrastim) Market?# Market Expansion?
North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Neupogen (filgrastim) Market 2025, By The Business Research Company:
Filgrastim Biosimilars Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report
Pegfilgrastim Biosimilars Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report
Chronic Lymphocytic Leukemia Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
